Skip to main content
SpringerLink
Log in

Neoadjuvant treatment of pancreatic ductal adenocarcinoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer is the subject of several ongoing randomized controlled trials (RCTs). Retrospective studies and completed RCTs favor the use of neoadjuvant therapy in pancreatic cancer. Yet, the optimal chemotherapy regimen has not been defined. The objective of this report is to provide a review of currently available study data of neoadjuvant therapy in pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–47.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

    Article  Google Scholar 

  3. Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current clinical strategies of pancreatic cancer treatment and open molecular questions. Int J Mol Sci. 2019;20(18):4543.

    Article  CAS  Google Scholar 

  4. Zaky AM, Wolfgang CL, Weiss MJ, Javed AA, Fishman EK, Zaheer A. Tumor-vessel relationships in pancreatic ductal adenocarcinoma at multidetector CT: different classification systems and their influence on treatment planning. Radiographics. 2017;37(1):93–112.

    Article  Google Scholar 

  5. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.

    Article  Google Scholar 

  6. Rhee H, Park MS. The role of imaging in current treatment strategies for pancreatic adenocarcinoma. Korean J Radiol. 2021;22(1):23.

    Article  Google Scholar 

  7. Marion-Audibert AM, Vullierme MP, Ronot M, Mabrut JY, Sauvanet A, Zins M, et al. Routine MRI with DWI sequences to detect liver metastases in patients with potentially resectable pancreatic ductal carcinoma and normal liver CT: a prospective multicenter study. Am J Roentgenol. 2018;211(5):W217–25.

    Article  Google Scholar 

  8. Tzeng CWD, Cao HST, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16–25.

    Article  Google Scholar 

  9. Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.

    Article  Google Scholar 

  10. Bakens MJ, Geest LG, Putten M, Laarhoven HW, Creemers G, Besselink MG, et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 2016;5(10):2825–31.

    Article  CAS  Google Scholar 

  11. van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9.

    Article  Google Scholar 

  12. Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–58.

    Article  CAS  Google Scholar 

  13. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(8):1028–61.

    Article  Google Scholar 

  14. Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(4):1129.

    Article  CAS  Google Scholar 

  15. Lee YS, Lee JC, Yang SY, Kim J, Hwang JH. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis. Sci Rep. 2019;9(1):15662.

    Article  Google Scholar 

  16. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei ACC, Raoul JL, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018;36(18_suppl):LBA4001.

    Article  Google Scholar 

  17. Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM, et al. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: a propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120(6):976–84.

    Article  Google Scholar 

  18. Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515–22.

    Article  Google Scholar 

  19. Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–12.

    Article  Google Scholar 

  20. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16.

    Article  Google Scholar 

  21. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22.

    Article  Google Scholar 

  22. Ye M, Zhang Q, Chen Y, Fu Q, Li X, Bai X, et al. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB. 2020;22(6):821–32.

    Article  Google Scholar 

  23. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.

    Article  CAS  Google Scholar 

  24. Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;02233:21.

    Google Scholar 

  25. Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481–6.

    Article  Google Scholar 

  26. Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant treatment strategies in resectable pancreatic cancer. Cancers. 2021;13(18):4724.

    Article  CAS  Google Scholar 

  27. Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial—1 (NorPACT-1))—study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017;17(1):94.

    Article  Google Scholar 

  28. Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, et al. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer—the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 2018;18(1):1298.

    Article  CAS  Google Scholar 

  29. Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy—a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer. 2018;18(1):762.

    Article  Google Scholar 

  30. Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC‑2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21(1):300. for the Dutch Pancreatic Cancer Group.

    Article  CAS  Google Scholar 

  31. Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, et al. Value of neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma. J Clin Oncol. 2021;39(34):3773–7.

    Article  CAS  Google Scholar 

  32. Hill CS, Rosati LM, Hu C, Fu W, Sehgal S, Hacker-Prietz A, et al. Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic outcomes compared with chemotherapy alone for patients with borderline resectable or locally advanced pancreatic adenocarcinoma without increasing perioperative toxicity. Ann Surg Oncol. 2022;29(4):2456–68.

    Article  Google Scholar 

  33. Arcelli A, Buwenge M, Macchia G, Bertini F, Guido A, Deodato F, et al. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: a multicenter case-control study (PAULA-1). Cancer Med. 2020;9(21):7879–87.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Hepato-Pancreato-Biliary Center, Health Network Vienna, Clinic Favoriten, Kundratstr. 3, 1100, Vienna, Austria

    Katharina Kosma, Sabine Thalhammer & Thomas Gruenberger

Authors
  1. Katharina Kosma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabine Thalhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Gruenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katharina Kosma.

Ethics declarations

Conflict of interest

K. Kosma, S. Thalhammer and T. Gruenberger declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kosma, K., Thalhammer, S. & Gruenberger, T. Neoadjuvant treatment of pancreatic ductal adenocarcinoma. memo 15, 219–223 (2022). https://doi.org/10.1007/s12254-022-00832-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00832-7

Keywords

Search

Navigation